Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Direct Oral Anticoagulants and Mortality in Atrial Fibrillation

Martin Ellis, MD, Sergienko Ruslan, Hammerman Ariel, Sari Greenberg-Dotan, Erez Battat, Orly Hamburger-Avnery, MD, Dan Greenberg, Arbel Ronen

Blood (2018) 132 (Supplement 1): 5061.

https://doi.org/10.1182/blood-2018-99-111182

Published: 2018

Journal Articles

Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis

Joseph R. Shaw, MD, Tinghua Zhang, M.Sc., Gregoire Le Gal, MD PhD, James Douketis, MD, Marc Carrier, MD MSc

Blood (2018) 132 (Supplement 1): 1234.

https://doi.org/10.1182/blood-2018-99-111698

Published: 2018

Journal Articles

Use of Anticoagulation in Patients with Immune Thrombocytopenia

Amaris K. Balitsky, John G Kelton, MD FRCPC, Ishac Nazy, PhD, Brandon Aubie, Rumi Clare, BSc, Anushka M Jaffer, BSc, Donald M Arnold, MD

Blood (2017) 130 (Supplement 1): 2313.

https://doi.org/10.1182/blood.V130.Suppl_1.2313.2313

Published: 2017

Journal Articles

Data of Real-Life Anticoagulant Treatment in Patients Diagnosed with Nonvalvular Atrial Fibrillation and Secondary Prevention of Venous Thromboembolic Disease with Edoxaban: Experience in Our Center

Maria Almudena Garcia Ruiz, Marta Rivas Luque, Pablo Romero Garcia, MDCINE Resident, Manuel Jurado, MD PhD

Blood (2017) 130 (Supplement 1): 4920.

https://doi.org/10.1182/blood.V130.Suppl_1.4920.4920

Published: 2017

Journal Articles

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Tracy E Wiczer, PharmD, BCOP, Lauren B Levine, PharmD, BCOP, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Anli McCoy, PharmD, Kami J. Maddocks, MD, Beth A Christian, MD, Kerry A. Rogers, MD, Leslie Andritsos, MD, Samantha Jaglowski, MD MPH, Steven M Devine, MD, Pierluigi Porcu, MD, Jennifer A. Woyach, MD, Jeffrey Jones, MD MPH, Michael R. Grever, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 2040.

https://doi.org/10.1182/blood.V128.22.2040.2040

Published: 2016

Journal Articles

Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study

Martin H. Ellis, MD, Orly Avnery, MD, Estela Derazne, MSc, Erez Battat, Sari Greenberg Dotan, Ariel Hammerman, John Eikelboom, MD, Jeffrey S. Ginsberg, MD, Jack Hirsh, MD

Blood (2016) 128 (22): 2617.

https://doi.org/10.1182/blood.V128.22.2617.2617

Published: 2016

Journal Articles

Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review

Deborah M. Siegal, MD MSc, Ron Movilla, Reda Siddiqui, Rebecca Barty, MLT, CTRC, Mark A. Crowther, MD MSc, FRCPC, Nancy M Heddle, MSc

Blood (2015) 126 (23): 1137.

https://doi.org/10.1182/blood.V126.23.1137.1137

Published: 2015

Journal Articles

Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs

Jeffrey Paul Liles, MS, Christopher Wanderling, Jordan Lee Liles, Debra Hoppensteadt, PhD, Jawed Fareed, PhD, Daneyal Syed, Mushabbar Syed, MD

Blood (2015) 126 (23): 4731.

https://doi.org/10.1182/blood.V126.23.4731.4731

Published: 2015

Journal Articles

Gihp-Naco Prospective Registry: Characterization and Care of Major Bleeding in Patients Treated By Direct Oral Anticoagulants

Gilles Pernod, Pierre Albaladejo, Charles-Marc Samama, Pierre-Marie Sie, MD PhD, jean Luc Bosson

Blood (2014) 124 (21): 2877.

https://doi.org/10.1182/blood.V124.21.2877.2877

Published: 2014

Journal Articles

Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study

Martin H. Ellis, MD, Tsipora Neumann, Jeffrey S Ginsberg, MD, John W Eikelboom, MBBS, MSc, FRACP, FRCPA, Haim Bitterman, Ariel Hammerman, Erez Battat, Sari Greenberg, Jack Hirsh, MD

Blood (2014) 124 (21): 343.

https://doi.org/10.1182/blood.V124.21.343.343

Published: 2014

Journal Articles

FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery

Joseph Shaw, B.Sc, Gregoire Le Gal, MDPhD, Melanie Tokessy, Nancy Cober, Elianna Saidenberg, MD, Marc Carrier, MDMSc, Lana Castellucci, MDMSc

Blood (2014) 124 (21): 4259.

https://doi.org/10.1182/blood.V124.21.4259.4259

Published: 2014

Journal Articles

FEIBA™ for Reversal of Direct Oral Anticoagulant Associated Major Bleeding

Joseph Shaw, B.Sc, Gregoire Le Gal, MDPhD, Melanie Tokessy, Nancy Cober, Elianna Saidenberg, MD, Marc Carrier, MDMSc, Lana Castellucci, MDMSc

Blood (2014) 124 (21): 1540.

https://doi.org/10.1182/blood.V124.21.1540.1540

Published: 2014

Journal Articles

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Franziska Ebertz, Sebastian Werth, MD, Christina Köhler, MD, Franziska Michalski, Ulrike Hänsel, Luise Tittl, Katharina Daschkow, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2014) 124 (21): 1541.

https://doi.org/10.1182/blood.V124.21.1541.1541

Published: 2014

Journal Articles

Comparison of Cost-Effectiveness of Anticoagulation with Dabigatran, Rivaroxaban and Apixaban in Patients with Non-Valvular Atrial Fibrillation Across Countries

Martin Krejczy, Job Harenberg, Prof., Dr., Svetlana Marx, Konrad Obermann, Prof., Dr., Martin Wehling, Prof., Dr.

Blood (2012) 120 (21): 1164.

https://doi.org/10.1182/blood.V120.21.1164.1164

Published: 2012

Journal Articles

Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Sebastian Werth, MD, Christina Koehler, Vera Gelbricht, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 1156.

https://doi.org/10.1182/blood.V120.21.1156.1156

Published: 2012

Journal Articles

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Vera Gelbricht, Sebastian Werth, MD, Christina Koehler, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 502.

https://doi.org/10.1182/blood.V120.21.502.502

Published: 2012

Journal Articles

Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin

Kevin M Francis, Kimberly Siu, MD, MPH, Chen Yu, Hasmik Alvrtsyan, MS, Yajing Rao, MS, David R Walker, PhD, Stephen D Sander, PharmD, Martin Zalesak, M.D., Ph.D., Gavin Miyasato, MS, Herman Sanchez, MBA

Blood (2012) 120 (21): 365.

https://doi.org/10.1182/blood.V120.21.365.365

Published: 2012

Journal Articles

Clinical Performance of Bleeding Risk Scores for Predicting Major and Clinically Relevant Non-Major Bleeding Events in Patients Receiving Oral Anticoagulant Therapy

Sarag Burgess, BScPharm, Natalie Crown, PharmD, Martha L Louzada, BSc, MD, MSc, George Dresser, MD PhD, Richard Kim, MD, Alejandro Lazo-Langner, MD, MSc

Blood (2011) 118 (21): 2311.

https://doi.org/10.1182/blood.V118.21.2311.2311

Published: 2011

Journal Articles

Incidence of Vascular Outcomes in Patients with Atrial Fibrillation,

Arlene M Gallagher, Tarita Murray-Thomas, Andreas Clemens, MD, Ackermann Diana, Dorothee B Bartels, PhD, MSc

Blood (2011) 118 (21): 4223.

https://doi.org/10.1182/blood.V118.21.4223.4223

Published: 2011

Journal Articles

Oral Anticoagulation In Patients with Atrial Fibrillation. Long-Term Follow-up

Cecilia Claudia Colorio, Dolores Patricia Puente, Andrea Silvia Rossi, Gonzalo Pombo, Eduardo Guevara, Marta Martinuzzo, Ricardo Forastiero

Blood (2010) 116 (21): 4392.

https://doi.org/10.1182/blood.V116.21.4392.4392

Published: 2010

NARROW

Direct Oral Anticoagulants and Mortality in Atrial Fibrillation

Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis

Use of Anticoagulation in Patients with Immune Thrombocytopenia

Data of Real-Life Anticoagulant Treatment in Patients Diagnosed with Nonvalvular Atrial Fibrillation and Secondary Prevention of Venous Thromboembolic Disease with Edoxaban: Experience in Our Center

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study

Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review

Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs

Gihp-Naco Prospective Registry: Characterization and Care of Major Bleeding in Patients Treated By Direct Oral Anticoagulants

Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study

FEIBA™ for Patients on Direct Oral Anticoagulants Requiring Urgent Surgery

FEIBA™ for Reversal of Direct Oral Anticoagulant Associated Major Bleeding

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Comparison of Cost-Effectiveness of Anticoagulation with Dabigatran, Rivaroxaban and Apixaban in Patients with Non-Valvular Atrial Fibrillation Across Countries

Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin

Clinical Performance of Bleeding Risk Scores for Predicting Major and Clinically Relevant Non-Major Bleeding Events in Patients Receiving Oral Anticoagulant Therapy

Incidence of Vascular Outcomes in Patients with Atrial Fibrillation,

Oral Anticoagulation In Patients with Atrial Fibrillation. Long-Term Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only